Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension

Journal of Hypertension

Volumn 30, Issue 1, 2012, Pages 210-216

  Ma, Ruixin ^a   Yu, Jing ^a   Xu, Dian ^a   Yang, Longquan ^a   Lin, Xin ^a   Zhao, Feng ^a   Bai, Feng ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

combination therapy; felodipine; hypertension; oxidative stress; sexual dysfunction

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; APRAVEL; ESTRADIOL; FELODIPINE; IRBESARTAN; MALONALDEHYDE; METOPROLOL; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; ORGASM; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL AROUSAL; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 83555173554     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834e1e2e     Document Type: Article

References (38)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
3. Liu L, Gong L. Chinese guidelines for prevention and treatment of hypertension (revision 2005). Beijing, China: People's Medical Publishing House; 2006.
4. Suzuki H, Tominaga T, Kumagai H, Saruta T. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl 1988; 6:S649-S651. (Pubitemid 19067433)
5. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2: 539-543.
6. Fogari R, Preti P, Derosa G, MarasiG, Zoppi A, Rinaldi A, Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58:177-180. (Pubitemid 34639571)
7. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2:29-34. (Pubitemid 38112142)
8. Kutmec C, Yurtsever S. Effects of sexual function of essential hypertensions in women. Eur J Cardiovasc Nurs 2011; 10:56-63.
9. Doumas M, Tsiodras S, Tsakiris A, Douma S, Chounta A, Papadopoulos A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens 2006; 24:2387-2392. (Pubitemid 44684686)
10. Jeremy JY, Jones RA, Koupparis AJ, Hotston M, Persad R, Angelini GD, Shukla N. Reactive oxygen species and erectile dysfunction: possible role of NADPH oxidase. Int J Impot Res 2007; 19:265-280. (Pubitemid 46701453)
11. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 2006; 27:335-347. (Pubitemid 43667981)
12. Shin D, Pregenzer G Jr, Gardin JM. Erectile dysfunction: a disease marker for cardiovascular disease. Cardiol Rev 2011; 19:5-11.
13. Dincer Y, Sekercioglu N, Pekpak M, Gunes KN, Akcay T. Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease. Ren Fail 2008; 30:1006-1011.
14. Miyashita Y, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009; 16:621-626.
15. Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 2008; 31:271-279. (Pubitemid 351461107)
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revised. Washington, DC: American Psychiatric Press, Inc.; 2000.
17. Bramer GR. International statistical classification of diseases and related health problems. Tenth revision. World Health Stat Q 1988; 41:32-36.
18. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26:191-208. (Pubitemid 30194541)
19. Takahashi M, Inokuchi T, Watanabe C, Saito T, Kai I. The Female Sexual Function Index (FSFI): development of a Japanese Version. J Sex Med 2011; 8:2246-2254.
20. Sun X, Li C, Jin L, Fan Y, Wang D. Development and validation of chinese version of female sexual function index in a chinese population: a pilot study. J Sex Med 2011; 8:1101-1111.
21. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 2000; 50:315-321. (Pubitemid 32289090)
22. de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010; 24:373-379.
23. Duncan LE, Lewis C, Smith CE, Jenkins P, Nichols M, Pearson TA. Sex, drugs, and hypertension: a methodological approach for studying a sensitive subject. Int J Impot Res 2001; 13:31-40. (Pubitemid 32274648)
24. Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, Mugellini A. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004; 17:77-81. (Pubitemid 38064765)
25. Weseler AR, Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr Hypertens Rep 2010; 12:154-161.
26. Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. Coron Artery Dis 2001; 12:455-461. (Pubitemid 32977815)
27. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 2008; 12:135-142.
28. Mansego ML, Solar Gde M, Alonso MP, Martinez F, Saez GT, Escudero JC, et al. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens 2011; 29:492-500.
29. Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials. Circulation 2010; 121:1439-1446.
30. Agarwal A, Gupta S, Sikka S. The role of free radicals and antioxidants in reproduction. Curr Opin Obstet Gynecol 2006; 18:325-332. (Pubitemid 43864734)
31. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005; 3:28.
32. Germano G, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M, et al. Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. J Hypertens 2004; 22:1151-1156. (Pubitemid 38721007)
33. Jonsson G, Abdelnoor M, Seljeflot I, Arnesen H, Hostmark AT, Kjeldsen SE, et al. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in postmyocardial infarction patients. J Cardiovasc Pharmacol 2007; 49:27-32. (Pubitemid 46184328)
34. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25:731-741. (Pubitemid 46398866)
35. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24:591-596. (Pubitemid 43261924)
36. Kawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 2004; 287: H1003-H1012. (Pubitemid 39096644)
37. Mimoun S, Wylie K. Female sexual dysfunctions: definitions and classification. Maturitas 2009; 63:116-118.
38. Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology 2009; 112:174-177.